BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of…
Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors
December 04, 2025 07:00 ET | Source: Vaxil Bio Ltd. Not for…
THE U.S. POINTER STRUCTURED HEALTHY LIFESTYLE PROGRAM — PREVIOUSLY SHOWN TO IMPROVE COGNITION — MAY ALSO IMPROVE SLEEP APNEA, BLOOD PRESSURE REGULATION, AND COGNITIVE RESILIENCE
- Two-year lifestyle intervention "recipe" tested in three NIH-funded ancillary studies -Key…
Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI
September 26, 2025 15:57 ET | Source: Scilex Holding Company PALO ALTO,…
Boehringers HERNEXEOS approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
This press release is not intended for UK and US media. HERNEXEOS® (zongertinib…
Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilexs Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a f
June 23, 2025 16:50 ET | Source: Scilex Holding Company PALO ALTO,…
